Gapping up
In reaction to earnings/guidance:
- LC +34.2%, WOLF +15%, MXL +9.3%, BUD +9.1%, ALGN +8.9% (also announces new study that validates benefits of iTero 5D), CYH +8.8%, UCTT +8.5%, F +8.3% (also co will reinstate dividend starting in Q4), SNBR +7.9%, WPP +7.2%, CCS +6.9%, ETD +4.6%, TYL +4.6%, STM +4.5%, OSTK +4.5%, PI +4.4%, NOK +4.2%, DQ +4.2%, SU +4.1% (also increases dividend and share buyback authorization), KLAC +4%, SCI +4%, BOOT +3.9% (also names new CFO), FCN +3.9%, ADS +3.8%, CLVT +3.7%, LH +3.7%, MC +3.6%, MTH +3.4%, MTLS +3.4%, CG +3.3%, CG +3.3%, HBAN +3.3%, ALSN +2.9%, DRE +2.8%, CMCSA +2.7%, EXR +2.6%, ASX +2.6%, IRBT +2.5%, STC +2.5%, MRK +2.4%, BC +2.3%, XLNX +2.2%, PBF +2.1%, FLWS +2%, ALGT +1.9%, AOS +1.9%, SONY +1.8%, TAK +1.7%, CHX +1.6%, CPG +1.6%, LYG +1.5%, TAP +1.4%, INVH +1.3%, URI +1.3%, RJF +1.1%, HSY +1.1%, MOH +1%, NLY +0.9%, WH +0.9%, SNY +0.9%, TROW +0.9%, YUMC +0.8%, .
Other news:
- HCWB +152.4% (receives FDA clearance to proceed with Phase 1b trial of HCW9218)
- ETON +12.6% (announces that it has acquired U.S. marketing rights to carglumic acid tablets)
- PHAT +7.4% (withdraws public offering due to market condtions)
- TDAC +5.7% (expects $63 mln in cash proceeds from combination with Lottery.com)
- MIME +5.2% (mulling options including potential sale according to WSJ)
- DDD +4% (acquires Volumetric Biotech for up to $400 mln;also expands bioprinting program with UTHR)
- LEV +3.7% (receives purchase order for 39 electric vehicles from Groupe Autocar Jeannois)
- INSE +3.5% (signs contract with MLB Players Alumni Assn)
- VRAY +3.4% (presented new outcomes data demonstrating prolonged survival for inoperable pancreatic cancer patients)
- GSK +2% (GlaxoSmithKline and Pfizer's ViiV Healthcare presents interim data showing for Vocabria and Rekambys)
- QS +1.5% (announces release of third-party test results for solid-state lithium-metal battery cells) .
Analyst comments:
- TER +3.6% (upgraded to Outperform from Market Perform at Cowen)
- ES +2.2% (upgraded to Neutral from Underperform at Mizuho)
- NSC +1.2% (upgraded to Buy from Neutral at BofA Securities)
- PCAR +0.9% (upgraded to Outperform from Neutral at Credit Suisse)